Specific product names of new drugs are being mentioned at the National Assembly audit and public petitions calling for the application of reimbursement for specific drugs have gathered 50,000 consents.

Such activities, which would not have happened 5 years ago, are actually arising in Korea. The emergence of government affairs (GA) and patient advocacy (PA) managers are not irrelevant to the rise of such new drug issues and are more fundamentally related to the industry’s entry into an era of high-priced new drugs.

◆Awakening of the patients and rising public interest=" Please doctor, you are our only hope. Please save me.’

Times have changed. Patients and their